INmune Bio (INMB) 10-K2021 FY Annual report

Filed: 3 Mar 22, 4:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ADi, allele, AmplifyBio, anecdotal, avidity, axon, axonal, Battery, belief, BIOTM, Blvd, BME, Boca, bona, bond, borrowed, Boulder, bullousa, burn, Century, CIML, cocktail, Cogstate, Colorado, commandeered, comparison, concurrent, Contactin, CORDstrom, cortical, Delta, density, diffusivity, disarray, disfiguring, DNTNF, drew, DTI, easy, ECOG, EEG, eleven, EMACC, encouraging, enrichment, erythrocyte, ESR, evidencing, Fehneger, fermentation, fiber, fide, FL, frozen, GAS, gray, Great, hemoglobin, highest, HSCT, hundred, ID, ineligible, INKmuneTM, Innovation, intracellular, loan, lyse, mask, MCI, Mizner, mlNK, NE, neurofilament, neurogranin, neutrophil, NPI, Omicron, Ormond, phagocytic, phenotype, phospho, platelet, polyglucan, preformed, prepay, prepayment, proceed, pseudokine, PSEUDOKINETM, quantifying, Quarantine, radial, Raton, reactivate, repayment, RESERVED, reward, sedimentation, Silicon, skin, speech, stay, substance, substrate, SVB, TNBC, triple, underwent, unpaid, Valley, verification, Vetter, VIII, XProTM, young

Removed: addressable, advancement, aggression, AmJ, amortization, appointed, array, artificially, assay, attacking, breath, CA, calculation, capacity, cardiovascular, cataloged, catheter, CCGTT, clarity, companion, conceived, concentrated, conjugation, constituting, constitutively, counteract, Crucially, deal, defective, deliver, dossier, downregulating, dying, EP, EPO, eventually, evolution, exercising, exhaled, exhausted, extensively, fatigue, fatty, fit, formation, Galileo, Hematol, HYPERGLYCEMIA, illustrative, immunoregulatory, indwelling, inhibitory, intraperitoneal, Italian, iv, JI, job, JP, JPO, KR, lacking, LAK, launched, learning, leukemic, listed, lytic, Mab, MabNK, manageable, mature, maximum, MHC, NAFLD, NantKwest, network, NEUROLOGICAL, observation, Opdivoo, organ, permanently, poised, predicting, presence, prognostic, promulgated, Prospect, protective, rarely, reagent, removed, reversed, reversing, Sabry, sample, scaled, schematic, Seaboard, secrete, segregation, Serial, signature, stimulating, sublicense, survive, TBD, Title, undergoing, vast, VAT, virtually

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated INMB transcripts

INMB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of INmune Bio, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David J. Moss, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

March 3, 2022	/s/ David J. Moss
	David J. Moss
	Chief Financial Officer
	(Principal Financial and Accounting Officer)